Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Non-Hodgkins Lymphoma
MeSH terms: Lymphoma; Lymphoma, Non-Hodgkin
Intervention: Velcade; Temsirolimus
Intervention description: Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22); Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
Intervention MeSH terms: Sirolimus; Bortezomib; Temsirolimus; MTOR Inhibitors
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 40.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: velcade; temsirolimus; non-hodgkins lymphoma

Summary:

      The investigators want to find out if the drugs Velcade and temsirolimus given together are
      effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for
      certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and
      temsirolimus for renal cell carcinoma) but are not currently approved in combination for
      B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs
      together will improve the period of time that the patient's cancer is stopped or slowed from
      growing and causing symptoms.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory B-cell non-Hodgkin lymphoma which includes: diffuse large
             B-cell lymphoma; primary mediastinal large B-cell lymphoma; follicular lymphoma (grade
             1, 2 or 3); mantle cell lymphoma; small lymphocytic lymphoma; marginal zone lymphoma;
             lymphoplasmacytic lymphoma; B-cell lymphoblastic lymphoma; or Burkitt lymphoma.
             "Grey-zone" lymphomas must be approved by the Wisconsin Oncology Network (WON) Study
             Chair or Principal Investigator prior to enrollment.

          -  At least one measurable tumor mass (>1.5 cm in the long axis and > 1.0 cm in the short
             axis) that has not been previously irradiated, or has grown since previous
             irradiation.

          -  Documented relapse or progression following prior antineoplastic therapy.

          -  No clinical or documented radiographic evidence of central nervous system lymphoma.

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0-2.

          -  The following clinical laboratory values within 14 days prior to enrollment:

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109 cells / L

          -  Platelets ≥ 100 x 109 cells / L

          -  Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3X the upper limit of
             normal (ULN)

          -  Total bilirubin ≤ 2X the upper limit of normal (ULN).

          -  Calculated creatinine clearance ≥40 mL/min (using the Cockcroft-Gault equation).

          -  Female subjects must be either post-menopausal for at least 1 year or surgically
             sterilized, agree to practice 2 effective methods of contraception from the time of
             signing the informed consent form through 30 days after the last dose of Velcade, or
             agree to completely abstain from heterosexual intercourse.

          -  Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to
             1 of the following: practice effective barrier contraception during the entire study
             treatment period and through a minimum of 30 days after the last dose of study drug,
             or completely abstain from heterosexual intercourse.

        Exclusions:

          -  Antineoplastic, experimental, or radiation therapy within 14 days prior to enrollment,
             or 21 days prior to Day 1 of Cycle 1.

          -  Radioimmunoconjugates within 10 weeks of Day 1 of Cycle 1.

          -  Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or any prior
             history of allogeneic stem cell transplant.

          -  Platelet transfusion within 7 days of Day 1 of Cycle 1.

          -  Ongoing therapy with glucocorticoids. Prednisone ≤15 mg per day or its equivalent is
             allowed.

          -  Patient has Grade 2 or greater peripheral neuropathy within 14 days before enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities.

          -  Patient has hypersensitivity to Velcade, boron or mannitol.

          -  Female subjects that are pregnant or breast-feeding.

          -  Serious medical or psychiatric illness that is likely to interfere with participation

          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

          -  Prior therapy with both Velcade and temsirolimus. Patients who have previously been
             treated with either Velcade or temsirolimus (but not both) are eligible.

          -  Radiation therapy within 3 weeks before randomization.

          -  Patients must not be taking the following strong CyP3A inducers at study entry:
             phenytoin, phenobarbital, rifampin, carbamazepin, rifabutin, rifampicin, a one week
             washout period is required.